What is Veracyte's G&A?

Veracyte (VCYT) reported G&A of $23.68M in Q1 2026.

How has Veracyte's G&A changed year-over-year?

Veracyte's G&A decreased by 30.0% year-over-year, from $33.81M to $23.68M.

What is the long-term trend for Veracyte's G&A?

Over 4 years (2021 to 2025), Veracyte's G&A has grown at a 2.2% compound annual growth rate (CAGR), from $101.35M to $110.78M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Veracyte VCYT G&A

G&A at other companies

Guardant HealthGH

$57.93M+23.4%

Idexx LaboratoriesIDXX

$119.12M+30.1%

Adaptive BiotechnologiesADPT

$20.98M+20.6%

Lantheus HoldingsLNTH

$57.53M+1.3%

Segments

By segment

See full

Reportable Segment$23.68M-30.0%

Other financials

Income statement

See full

Revenue$139.1M+21.5%

Gross profit$101.2M+27.2%

Operating income$22.6M+680%

Net income$28.7M+307%

EPS (diluted)$0.35+289%

Balance sheet

See full

Cash & equivalents$264.8M+41.0%

Total debt$39.3M-22.1%

Total equity$1.3B+12.5%

Total assets$1.4B+9.2%

Cash flow

See full

Operating cash flow$35.2M+557%

CapEx$3.0M+62.8%

Free cash flow$32.3M+810%

Valuation

See full

Market cap$4.29B+10.7%

Profitability

See full

Gross margin70.9%+2.9pp

Operating margin14.3%+9.2pp

Net margin16.2%+9.1pp

FCF margin28.7%+11.7pp

Returns & leverage

See full

Return on equity6.9%+4.1pp

Debt / equity0×0.0×

Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veracyte's G&A?: Veracyte (VCYT) reported G&A of $23.68M in Q1 2026.
How has Veracyte's G&A changed year-over-year?: Veracyte's G&A decreased by 30.0% year-over-year, from $33.81M to $23.68M.
What is the long-term trend for Veracyte's G&A?: Over 4 years (2021 to 2025), Veracyte's G&A has grown at a 2.2% compound annual growth rate (CAGR), from $101.35M to $110.78M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.